Medical Care
Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Research Report 2025
- Mar 11, 25
- ID: 77668
- Pages: 81
- Figures: 82
- Views: 40
The global market for Non-Small Cell Lung Cancer Treatment (NSCLC) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Small Cell Lung Cancer Treatment (NSCLC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Small Cell Lung Cancer Treatment (NSCLC).
The Non-Small Cell Lung Cancer Treatment (NSCLC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Small Cell Lung Cancer Treatment (NSCLC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
Segment by Type
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Segment by Application
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Small Cell Lung Cancer Treatment (NSCLC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Small Cell Lung Cancer Treatment (NSCLC).
The Non-Small Cell Lung Cancer Treatment (NSCLC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Small Cell Lung Cancer Treatment (NSCLC) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
Segment by Type
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Segment by Application
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Angiogenesis Inhibitor
1.2.3 Epidermal Growth Factor Receptor Blocker
1.2.4 Kinase Inhibitor
1.2.5 Microtubule Stabilizer
1.2.6 Folate Antimetabolites
1.2.7 Others
1.3 Market by Application
1.3.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Adenocarcinoma
1.3.3 Squamous Cell Carcinoma
1.3.4 Large Cell Carcinoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Perspective (2020-2031)
2.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Growth Trends by Region
2.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Region (2020-2025)
2.2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2026-2031)
2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Dynamics
2.3.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Industry Trends
2.3.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
2.3.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
2.3.4 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue
3.1.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue (2020-2025)
3.1.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Players (2020-2025)
3.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue
3.4 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio
3.4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2024
3.5 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC) Head office and Area Served
3.6 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Product and Application
3.7 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Type
4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Type (2020-2025)
4.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2026-2031)
5 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Application
5.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Application (2020-2025)
5.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
6.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
6.4 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
7.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
7.4 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
8.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
9.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
9.4 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
10.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.1.4 AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.1.5 AbbVie Inc. Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.2.4 Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.2.5 Astellas Pharma Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.3.4 AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Avid Bioservices Inc.
11.4.1 Avid Bioservices Inc. Company Details
11.4.2 Avid Bioservices Inc. Business Overview
11.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.4.4 Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.4.5 Avid Bioservices Inc. Recent Development
11.5 Bayer Healthcare
11.5.1 Bayer Healthcare Company Details
11.5.2 Bayer Healthcare Business Overview
11.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.5.4 Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.5.5 Bayer Healthcare Recent Development
11.6 Biogen Inc.
11.6.1 Biogen Inc. Company Details
11.6.2 Biogen Inc. Business Overview
11.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.6.4 Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.6.5 Biogen Inc. Recent Development
11.7 Blueprint Medicines Corp
11.7.1 Blueprint Medicines Corp Company Details
11.7.2 Blueprint Medicines Corp Business Overview
11.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.7.4 Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.7.5 Blueprint Medicines Corp Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.8.4 Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & co Inc.
11.9.1 Merck & co Inc. Company Details
11.9.2 Merck & co Inc. Business Overview
11.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.9.4 Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.9.5 Merck & co Inc. Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.10.4 Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.11.4 Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.11.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Angiogenesis Inhibitor
1.2.3 Epidermal Growth Factor Receptor Blocker
1.2.4 Kinase Inhibitor
1.2.5 Microtubule Stabilizer
1.2.6 Folate Antimetabolites
1.2.7 Others
1.3 Market by Application
1.3.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Adenocarcinoma
1.3.3 Squamous Cell Carcinoma
1.3.4 Large Cell Carcinoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Perspective (2020-2031)
2.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Growth Trends by Region
2.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Region (2020-2025)
2.2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2026-2031)
2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Dynamics
2.3.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Industry Trends
2.3.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
2.3.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
2.3.4 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue
3.1.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue (2020-2025)
3.1.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Players (2020-2025)
3.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue
3.4 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio
3.4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2024
3.5 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC) Head office and Area Served
3.6 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Product and Application
3.7 Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Type
4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Type (2020-2025)
4.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2026-2031)
5 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Application
5.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Application (2020-2025)
5.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
6.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
6.4 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
7.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
7.4 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
8.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
9.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
9.4 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2020-2031)
10.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.1.4 AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.1.5 AbbVie Inc. Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.2.4 Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.2.5 Astellas Pharma Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.3.4 AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.3.5 AstraZeneca Recent Development
11.4 Avid Bioservices Inc.
11.4.1 Avid Bioservices Inc. Company Details
11.4.2 Avid Bioservices Inc. Business Overview
11.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.4.4 Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.4.5 Avid Bioservices Inc. Recent Development
11.5 Bayer Healthcare
11.5.1 Bayer Healthcare Company Details
11.5.2 Bayer Healthcare Business Overview
11.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.5.4 Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.5.5 Bayer Healthcare Recent Development
11.6 Biogen Inc.
11.6.1 Biogen Inc. Company Details
11.6.2 Biogen Inc. Business Overview
11.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.6.4 Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.6.5 Biogen Inc. Recent Development
11.7 Blueprint Medicines Corp
11.7.1 Blueprint Medicines Corp Company Details
11.7.2 Blueprint Medicines Corp Business Overview
11.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.7.4 Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.7.5 Blueprint Medicines Corp Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.8.4 Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 Merck & co Inc.
11.9.1 Merck & co Inc. Company Details
11.9.2 Merck & co Inc. Business Overview
11.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.9.4 Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.9.5 Merck & co Inc. Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.10.4 Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.10.5 Novartis Recent Development
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.11.4 Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
11.11.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Angiogenesis Inhibitor
Table 3. Key Players of Epidermal Growth Factor Receptor Blocker
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Microtubule Stabilizer
Table 6. Key Players of Folate Antimetabolites
Table 7. Key Players of Others
Table 8. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2020-2025)
Table 12. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2026-2031)
Table 14. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Trends
Table 15. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
Table 16. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
Table 17. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
Table 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players (2020-2025)
Table 20. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2024)
Table 21. Ranking of Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Headquarters and Area Served
Table 24. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Product and Application
Table 25. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2020-2025)
Table 29. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2026-2031)
Table 31. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2020-2025)
Table 33. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2026-2031)
Table 35. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 50. AbbVie Inc. Company Details
Table 51. AbbVie Inc. Business Overview
Table 52. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 53. AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 54. AbbVie Inc. Recent Development
Table 55. Astellas Pharma Company Details
Table 56. Astellas Pharma Business Overview
Table 57. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 58. Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 59. Astellas Pharma Recent Development
Table 60. AstraZeneca Company Details
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 63. AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. Avid Bioservices Inc. Company Details
Table 66. Avid Bioservices Inc. Business Overview
Table 67. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 68. Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 69. Avid Bioservices Inc. Recent Development
Table 70. Bayer Healthcare Company Details
Table 71. Bayer Healthcare Business Overview
Table 72. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 73. Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 74. Bayer Healthcare Recent Development
Table 75. Biogen Inc. Company Details
Table 76. Biogen Inc. Business Overview
Table 77. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 78. Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 79. Biogen Inc. Recent Development
Table 80. Blueprint Medicines Corp Company Details
Table 81. Blueprint Medicines Corp Business Overview
Table 82. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 83. Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 84. Blueprint Medicines Corp Recent Development
Table 85. Eli Lilly and Company Company Details
Table 86. Eli Lilly and Company Business Overview
Table 87. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 88. Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 89. Eli Lilly and Company Recent Development
Table 90. Merck & co Inc. Company Details
Table 91. Merck & co Inc. Business Overview
Table 92. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 93. Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 94. Merck & co Inc. Recent Development
Table 95. Novartis Company Details
Table 96. Novartis Business Overview
Table 97. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 98. Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 99. Novartis Recent Development
Table 100. Pfizer Inc. Company Details
Table 101. Pfizer Inc. Business Overview
Table 102. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 103. Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 104. Pfizer Inc. Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Picture
Figure 2. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type: 2024 VS 2031
Figure 4. Angiogenesis Inhibitor Features
Figure 5. Epidermal Growth Factor Receptor Blocker Features
Figure 6. Kinase Inhibitor Features
Figure 7. Microtubule Stabilizer Features
Figure 8. Folate Antimetabolites Features
Figure 9. Others Features
Figure 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application: 2024 VS 2031
Figure 12. Adenocarcinoma Case Studies
Figure 13. Squamous Cell Carcinoma Case Studies
Figure 14. Large Cell Carcinoma Case Studies
Figure 15. Non-Small Cell Lung Cancer Treatment (NSCLC) Report Years Considered
Figure 16. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region: 2024 VS 2031
Figure 19. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players in 2024
Figure 20. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2024
Figure 22. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 24. United States Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 28. Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2020-2031)
Figure 36. China Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 44. Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 48. Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. AbbVie Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 52. Astellas Pharma Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 53. AstraZeneca Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 54. Avid Bioservices Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 55. Bayer Healthcare Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 56. Biogen Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 57. Blueprint Medicines Corp Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 58. Eli Lilly and Company Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 59. Merck & co Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 60. Novartis Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 61. Pfizer Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Angiogenesis Inhibitor
Table 3. Key Players of Epidermal Growth Factor Receptor Blocker
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Microtubule Stabilizer
Table 6. Key Players of Folate Antimetabolites
Table 7. Key Players of Others
Table 8. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2020-2025)
Table 12. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2026-2031)
Table 14. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Trends
Table 15. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
Table 16. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
Table 17. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
Table 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players (2020-2025)
Table 20. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2024)
Table 21. Ranking of Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Headquarters and Area Served
Table 24. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Product and Application
Table 25. Global Key Players of Non-Small Cell Lung Cancer Treatment (NSCLC), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2020-2025)
Table 29. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Type (2026-2031)
Table 31. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2020-2025)
Table 33. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Application (2026-2031)
Table 35. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2026-2031) & (US$ Million)
Table 50. AbbVie Inc. Company Details
Table 51. AbbVie Inc. Business Overview
Table 52. AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 53. AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 54. AbbVie Inc. Recent Development
Table 55. Astellas Pharma Company Details
Table 56. Astellas Pharma Business Overview
Table 57. Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 58. Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 59. Astellas Pharma Recent Development
Table 60. AstraZeneca Company Details
Table 61. AstraZeneca Business Overview
Table 62. AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 63. AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 64. AstraZeneca Recent Development
Table 65. Avid Bioservices Inc. Company Details
Table 66. Avid Bioservices Inc. Business Overview
Table 67. Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 68. Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 69. Avid Bioservices Inc. Recent Development
Table 70. Bayer Healthcare Company Details
Table 71. Bayer Healthcare Business Overview
Table 72. Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 73. Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 74. Bayer Healthcare Recent Development
Table 75. Biogen Inc. Company Details
Table 76. Biogen Inc. Business Overview
Table 77. Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 78. Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 79. Biogen Inc. Recent Development
Table 80. Blueprint Medicines Corp Company Details
Table 81. Blueprint Medicines Corp Business Overview
Table 82. Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 83. Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 84. Blueprint Medicines Corp Recent Development
Table 85. Eli Lilly and Company Company Details
Table 86. Eli Lilly and Company Business Overview
Table 87. Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 88. Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 89. Eli Lilly and Company Recent Development
Table 90. Merck & co Inc. Company Details
Table 91. Merck & co Inc. Business Overview
Table 92. Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 93. Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 94. Merck & co Inc. Recent Development
Table 95. Novartis Company Details
Table 96. Novartis Business Overview
Table 97. Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 98. Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 99. Novartis Recent Development
Table 100. Pfizer Inc. Company Details
Table 101. Pfizer Inc. Business Overview
Table 102. Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Product
Table 103. Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025) & (US$ Million)
Table 104. Pfizer Inc. Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Non-Small Cell Lung Cancer Treatment (NSCLC) Picture
Figure 2. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type: 2024 VS 2031
Figure 4. Angiogenesis Inhibitor Features
Figure 5. Epidermal Growth Factor Receptor Blocker Features
Figure 6. Kinase Inhibitor Features
Figure 7. Microtubule Stabilizer Features
Figure 8. Folate Antimetabolites Features
Figure 9. Others Features
Figure 10. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application: 2024 VS 2031
Figure 12. Adenocarcinoma Case Studies
Figure 13. Squamous Cell Carcinoma Case Studies
Figure 14. Large Cell Carcinoma Case Studies
Figure 15. Non-Small Cell Lung Cancer Treatment (NSCLC) Report Years Considered
Figure 16. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region: 2024 VS 2031
Figure 19. Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Players in 2024
Figure 20. Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2024
Figure 22. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 24. United States Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 28. Germany Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (2020-2031)
Figure 36. China Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 44. Mexico Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Country (2020-2031)
Figure 48. Turkey Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. AbbVie Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 52. Astellas Pharma Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 53. AstraZeneca Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 54. Avid Bioservices Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 55. Bayer Healthcare Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 56. Biogen Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 57. Blueprint Medicines Corp Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 58. Eli Lilly and Company Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 59. Merck & co Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 60. Novartis Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 61. Pfizer Inc. Revenue Growth Rate in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Spatial Metabolomics Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global Pharmaceutical Process Analytical Technology (PAT) Software Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Global HASE Rheology Modifiers Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232